問卷

TPIDB > Search Result

Search Result

篩選

List

640Cases

2018-09-01 - 2026-10-02

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-13 - 2030-06-30

Phase III

Active
An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT]
  • Condition/Disease

    Primary Membranous Nephropathy (PMN)

  • Test Drug

    powder

Participate Sites
10Sites

Recruiting10Sites

2023-08-31 - 2032-02-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)
  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    Injection

Participate Sites
5Sites

Recruiting5Sites

2025-07-01 - 2030-10-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-06-30 - 2030-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites

2025-05-30 - 2027-07-12

Phase III

Active
SYNOVIIIUS: Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients with Hemophilia A
  • Condition/Disease

    Hemophilia A

  • Test Drug

    Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection

Participate Sites
3Sites

Recruiting3Sites

2021-08-01 - 2029-02-28

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-01-14 - 2026-07-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-10-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites